Prasugrel-d5 is intended for use as an internal standard for the quantification of prasugrel by GC- or LC-MS. Prasugrel is a prodrug form of the platelet purinergic P2Y12 receptor antagonist R-99224.1 Prasugrel (0.3 and 3 mg/kg) inhibits ex vivo washed platelet aggregation in rat platelet rich-plasma.2 In vivo, prasugrel prevents thrombus formation (ED50 = 0.68 mg/kg) and increases tail bleeding time in rats. Formulations containing prasugrel have been used in the prevention of blood clots.
1.Sugidachi, A., Asai, F., Yoneda, K., et al.Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747Br. J. Pharmacol.132(1)47-54(2001) 2.Sugidachi, A., Asai, F., Ogawa, T., et al.The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBr. J. Pharmacol.129(7)1439-1446(2000)